Luye Pharma of China to raise $763m in upcoming Hong Kong IPO
This article was originally published in Scrip
Executive Summary
The recent tension between Hong Kong and mainland China has little impact on business. In fact, the Hong Kong market has recently attracted a row of Chinese companies across industries to seek initial public offerings, and one of them is Luye Pharma, a fast growing private pharma based in Yantai, Shandong province.
You may also be interested in...
Luye Looks To Horizons Beyond Pharma, China
Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.
Chinese Appetite For Medtech Could Shrink In Face Of Uncertainty
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China’s Big And Small Next-Gen Sequencing Players Ride The Precision Medicine Wave
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.